The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma Naïve to B-cell Maturation Antigen (BCMA)-Directed Therapies: Results From Cohort A of the MagnetisMM-3 Study
December 11, 2022 ASH 2022 Hematology